These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 30551196)

  • 21. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy.
    Gye A; Lourenco RA; Goodall S
    Value Health; 2024 Apr; 27(4):415-424. PubMed ID: 38301961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.
    Lin JK; Lerman BJ; Barnes JI; Boursiquot BC; Tan YJ; Robinson AQL; Davis KL; Owens DK; Goldhaber-Fiebert JD
    J Clin Oncol; 2018 Nov; 36(32):3192-3202. PubMed ID: 30212291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis.
    Carey N; Leahy J; Trela-Larsen L; McCullagh L; Barry M
    Int J Technol Assess Health Care; 2022 Jul; 38(1):e56. PubMed ID: 35815435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
    Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
    Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
    Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland.
    Moradi-Lakeh M; Yaghoubi M; Seitz P; Javanbakht M; Brock E
    Adv Ther; 2021 Jun; 38(6):3427-3443. PubMed ID: 34021886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
    Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
    Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
    Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
    Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
    Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
    Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
    Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma.
    Yamamoto C; Minakata D; Yokoyama D; Furuki S; Noguchi A; Koyama S; Oyama T; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Hyodo K; Toda Y; Ito S; Nagayama T; Umino K; Morita K; Ashizawa M; Ueda M; Hatano K; Sato K; Ohmine K; Fujiwara SI; Kanda Y
    Transplant Cell Ther; 2024 Jan; 30(1):118.e1-118.e15. PubMed ID: 37802181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.
    Thavorn K; Thompson ER; Kumar S; Heiskanen A; Agarwal A; Atkins H; Shorr R; Hawrysh T; Chan KK; Presseau J; Ollendorf DA; Graham ID; Grimshaw JM; Lalu MM; Nochaiwong S; Fergusson DA; Hutton B; Coyle D; Kekre N
    Value Health; 2024 Aug; 27(8):1149-1173. PubMed ID: 38641057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical analysis of long-term survival and influencing factors of chimeric antigen receptor T-cell therapy in relapsed/refractory acute B-cell lymphoblastic leukemia].
    Wang Y; Gao QY; Wang H; Zhang D; Gao Y; Miao YD; Zhai XH; Hu XX; Rui XL; Zhang WH
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):800-804. PubMed ID: 38049330
    [No Abstract]   [Full Text] [Related]  

  • 38. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2017 Oct; 9(13):1115-1125. PubMed ID: 29032733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement.
    Gye A; Goodall S; De Abreu Lourenco R
    Pharmacoeconomics; 2023 Feb; 41(2):175-186. PubMed ID: 36266557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
    Ghorashian S; Kramer AM; Onuoha S; Wright G; Bartram J; Richardson R; Albon SJ; Casanovas-Company J; Castro F; Popova B; Villanueva K; Yeung J; Vetharoy W; Guvenel A; Wawrzyniecka PA; Mekkaoui L; Cheung GW; Pinner D; Chu J; Lucchini G; Silva J; Ciocarlie O; Lazareva A; Inglott S; Gilmour KC; Ahsan G; Ferrari M; Manzoor S; Champion K; Brooks T; Lopes A; Hackshaw A; Farzaneh F; Chiesa R; Rao K; Bonney D; Samarasinghe S; Goulden N; Vora A; Veys P; Hough R; Wynn R; Pule MA; Amrolia PJ
    Nat Med; 2019 Sep; 25(9):1408-1414. PubMed ID: 31477906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.